In-depth characterization of NK cell markers from CML patients who discontinued tyrosine kinase inhibitor therapy.
Sanchez MB, Vasconcelos Cordoba B, Pavlovsky C, Moiraghi B, Varela A, Custidiano R, Fernandez I, Freitas MJ, Ventriglia MV, Bendek G, Mariano R, Mela Osorio MJ, Pavlovsky MA, García de Labanca A, Foncuberta C, Giere I, Vera M, Juni M, Mordoh J, Sanchez Avalos JC, Levy EM, Bianchini M.
Sanchez MB, et al. Among authors: mordoh j.
Front Immunol. 2023 Sep 25;14:1241600. doi: 10.3389/fimmu.2023.1241600. eCollection 2023.
Front Immunol. 2023.
PMID: 37818372
Free PMC article.
Clinical Trial.